Chikungunya – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Chikungunya is a mosquito-borne viral disease that causes fever and severe joint pain.
Etiology-
Chikungunya is a viral disease transmitted to humans by infected
mosquitoes. It is caused by the chikungunya virus (CHIKV).
Epidemiology-
As of 13 February 2015, according to the Pan
American Health Organization, at least 182 deaths out of nearly 1.2 million
cases have been attributed to chikungunya virus in the Caribbean and other regions
of the Americas (overall case fatality rate 0,02%).
The competitive
landscape of Chikungunya includes country-specific approved as well as pipeline
therapies. Any asset/product-specific designation or review and Accelerated
Approval are being tracked and supplemented with analyst commentary.
KOLs
insights of Chikungunya across 8 MM market from the center of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Chikungunya
Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 MV-CHIK low dose Themis
Bioscience GmbH Phase 2
2 Inactivated Chikungunya virus vaccine 20 mcg Bharat Biotech International Limited Phase 1
3 Chikungunya Emergent
BioSolutions Phase 2
4 VLA1553 Valneva
Austria GmbH Phase 3
5 mRNA-1944 ModernaTX,
Inc. Phase 1
Comments
Post a Comment